Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortizatization of Intangibles: 2016-2025

Historic Amortizatization of Intangibles for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to $192,000.

  • Cartesian Therapeutics' Amortizatization of Intangibles fell 70.60% to $192,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 44.96%. This contributed to the annual value of $2.4 million for FY2024, which is 38.94% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Amortizatization of Intangibles is $192,000, which was up 2.67% from $187,000 recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Amortizatization of Intangibles peaked at $671,000 during Q4 2024, and registered a low of $184,000 during Q1 2025.
  • Its 3-year average for Amortizatization of Intangibles is $432,182, with a median of $436,000 in 2023.
  • Per our database at Business Quant, Cartesian Therapeutics' Amortizatization of Intangibles skyrocketed by 49.77% in 2024 and then tumbled by 70.60% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $287,000 in 2021, then soared by 41.81% to $407,000 in 2022, then climbed by 16.95% to $476,000 in 2023, then surged by 40.97% to $671,000 in 2024, then crashed by 70.60% to $192,000 in 2025.
  • Its Amortizatization of Intangibles was $192,000 in Q3 2025, compared to $187,000 in Q2 2025 and $184,000 in Q1 2025.